Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genaissance and Organon join forces to improve R&D
The companies will use Genaissance’s HAP Technology for pharmacogenetic research to discover genetic markers that show individual responses to drugs. They will then aim to create diagnostic tests
The companies will use Genaissance’s HAP Technology for pharmacogenetic research to discover genetic markers that show individual responses to drugs. They will then aim to create diagnostic tests
The deal is particularly significant for Geron, which has spent large sums of money on its mission to develop drugs to combat cancer and other major illnesses. Under
GDNF has been shown to protect the neurons that produce dopamine that becomes depleted in Parkinson’s patients. GDNF has also been shown to have a beneficial role in
In tests done on female mice and mice heart cells, Dr Ellis Levin and his UCI colleagues found that estrogen triggers molecular activity that blocks cardiac hypertrophy, or
Intravenous delivery of IL-2 protein is approved as a treatment for metastatic melanoma, but frequently causes severe side effects. The novel treatment approach being studied in this trial
The study concentrated on the direct activation of the human checkpoint kinase 2 (Chk2), and showed that this caused the death of cancer cells independently of chemotherapy. Previously,
In the study, nightly use of Lunesta resulted in statistically significant improvement, compared with placebo, in patient-reported measures of sleep. Women treated with Lunesta reported fewer nocturnal awakenings
A key monoclonal antibody clinically shown to play an important role in fighting juvenile diabetes, anti-CD3 targets an antigen expressed on T lymphocytes, the cells of the immune
The study will now enter a six-month treatment phase with 85 patients randomized to receive either eculizumab or placebo, with the final patient anticipated to complete the treatment
IFN-beta is an established treatment for multiple sclerosis; however its short life in human serum necessitates frequent injections for the patient, and has associated side effects. The next